O'NEIL PATRICK R. 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Patrick O'Neil Receives Award, Sells 6,179 Shares
What Happened
Patrick R. O'Neil, EVP, Chief Legal Officer & General Counsel of Ionis Pharmaceuticals (IONS), had 11,991 performance-based restricted stock units (PRSUs) vest on Jan 29, 2026 (awarded at $0). The next day (Jan 30, 2026) he sold 6,179 of those shares in open-market transactions at a weighted average price of $83.53, generating approximately $516,153 in gross proceeds. Net from these transactions, O'Neil retained 5,812 of the newly vested shares.
Key Details
- Transaction dates: Award/vesting 2026-01-29; Open-market sales 2026-01-30. Form filed 2026-02-02 (timely).
- Sale price: Weighted avg $83.53; sale prices ranged $83.48–$83.67. Total sale proceeds reported: $516,153.
- Award: 11,991 PRSUs vested at $0 reported price (performance-based award).
- Net retained from vesting: 11,991 vested − 6,179 sold = 5,812 shares retained.
- Footnote highlights:
- F1: Vesting represents PRSUs for a prior grant (reported Jan 18, 2023). The Compensation Committee certified performance at 167.27% of target based on relative total shareholder return versus peers (payout range 0%–200%).
- F2: The sale price is a weighted average; the reporting person can provide a breakdown of number of shares sold at each price within the $83.48–$83.67 range upon request.
- Total beneficial ownership after these transactions is not reported in the information provided.
Context
This filing shows a common pattern: a performance-based equity award vested and the insider sold a portion in the open market. The sale reduced his holdings from the vested award but left a remaining position of 5,812 shares from that vesting event. The Form 4 was filed within the required reporting window.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-29+11,991→ 78,162 total - Sale
Common Stock
[F2]2026-01-30$83.53/sh−6,179$516,153→ 71,983 total
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.48 to $83.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.